Document Detail


Phase II trial of carboplatin and tegafur (Ftorafur) as induction therapy in squamous-cell carcinoma of the head and neck.
MedLine Citation:
PMID:  2116084     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Cisplatin and 5-fluorouracil by continuous infusion combination produces a high response rate in squamous-cell carcinoma of the head and neck (SCCHN). Carboplatin (CBDCA) is a cisplatin analogue with lower emetic potential and nephrotoxicity, although the myelosuppression potential is higher. Tegafur (ftorafur, FT) is an analogue of 5-fluorouracil. It is absorbed well in its oral form and has moderate gastrointestinal and hematologic toxicity. This clinical trial tested the association of CBDCA i.v. plus FT p.o. in patients with SCCHN who had not been previously treated. Twenty-one patients were evaluable for response; the overall response was 62% (33% complete response, 29% partial response). Toxicity was moderate in most of the patients, although there was a treatment-related death.
Authors:
M Gonzalez-Baron; J Vicente; G Martin; A Artal; I Cebreiros; C Garcia-Giron; M Tomas; J Gavilan; V Martorell; P Zamora
Related Documents :
12597144 - Paclitaxel and carboplatin in neo-adjuvant and concomitant chemoradiotherapy in locally...
18156144 - Phase ii study of pemetrexed in combination with carboplatin in patients with malignant...
11990304 - Use of amifostine in the therapy of osteosarcoma in children and adolescents.
3002624 - Carboplatin (jm8) as a single agent and in combination in the treatment of small cell l...
17711444 - Ema-co chemotherapy for high-risk gestational trophoblastic neoplasia: a clinical analy...
9166554 - Factors influencing survival after gamma knife radiosurgery for patients with single an...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  American journal of clinical oncology     Volume:  13     ISSN:  0277-3732     ISO Abbreviation:  Am. J. Clin. Oncol.     Publication Date:  1990 Aug 
Date Detail:
Created Date:  1990-09-06     Completed Date:  1990-09-06     Revised Date:  2006-04-24    
Medline Journal Info:
Nlm Unique ID:  8207754     Medline TA:  Am J Clin Oncol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  277-9     Citation Subset:  IM    
Affiliation:
Department of Medicine, Hospital La Paz, Facultad de Medicina, Universidad Autonoma, Madrid, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / adverse effects,  therapeutic use*
Carboplatin
Carcinoma, Squamous Cell / drug therapy*
Drug Evaluation
Female
Head and Neck Neoplasms / drug therapy*
Humans
Injections, Intravenous
Male
Middle Aged
Organoplatinum Compounds / administration & dosage*,  adverse effects
Remission Induction
Tegafur / administration & dosage*,  adverse effects
Chemical
Reg. No./Substance:
0/Organoplatinum Compounds; 17902-23-7/Tegafur; 41575-94-4/Carboplatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Prophylactic effect of UFT on the recurrence of bladder cancer
Next Document:  Phase II trial of cisplatin and tegafur (Ftorafur) as initial therapy in squamous-cell carcinoma of ...